Chemotherapy: What is its role in meningioma?

Expert Review of Neurotherapeutics

Volumn 12, Issue 10, 2012, Pages 1189-1196

  Sherman, W J ^a   Raizer, J J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

bevacizumab; chemotherapy; erlotinib; gefitinib; hydroxyurea; IFN a; imatinib mesylate; meningioma; mifepristone; octreotide; somatostatin; tamoxifen

Indexed keywords

ALPHA INTERFERON; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR; FIGITUMUMAB; GEFITINIB; GESTAGEN; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IRINOTECAN; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE; PASIREOTIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; SOMATOSTATIN; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; VATALANIB; VINCRISTINE;

ANGIOGENESIS; BONE MARROW SUPPRESSION; BRAIN RADIOGRAPHY; BRAIN SURGERY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEMANGIOPERICYTOMA; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MENINGIOMA; MENINGEAL HEMANGIOPERICYTOMA; MENINGIOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; REVIEW; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYUREA; MENINGEAL NEOPLASMS; MENINGIOMA; SOMATOSTATIN;

EID: 84867822654     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.108     Document Type: Review

References (57)

1. Chamberlain MC, Blumenthal DT. Intracranial meningiomas: Diagnosis and treatment. Expert Rev. Neurother. 4(4), 641-648 (2004).
2. Kyritsis AP. Chemotherapy for meningiomas. J. Neurooncol. 29(3), 269-272 (1996).
3. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 62(7), 1210-1212 (2004).
4. de Robles P, McIntyre J, Kalra S et al. Methylation status of MGMT gene promoter in meningiomas. Cancer Genet. Cytogenet. 187(1), 25-27 (2008).
5. Gupta V, Su YS, Samuelson CG et al. Irinotecan: A potential new chemotherapeutic agent for atypical or malignant meningiomas. J. Neurosurg. 106(3), 455-462 (2007).
6. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J. Neurooncol. 78(3), 271-276 (2006).
7. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J. Neurosurg. 84(5), 733-736 (1996).
8. Schrell UM, Rittig MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg. 86(5), 845-852 (1997).
9. Schrell UM, Rittig MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 86(5), 840-844 (1997).
10. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J. Neurooncol. 49(2), 165-170 (2000).
11. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J. Clin. Neurosci. 9(2), 156-158 (2002).
12. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg. 97(2), 341-346 (2002).
13. Loven D, Hardoff R, Sever ZB et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J. Neurooncol. 67(1-2), 221-226 (2004).
14. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: A retrospective case series. J. Neurooncol. 104(3), 765-771 (2011).
15. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J. Neurooncol. 107(2), 315-321 (2012).
16. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG. Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: Results of a pilot study. J. Neurooncol. 74(2), 157-165 (2005).
17. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J. Clin. Oncol. 26(2), 279-282 (2008).
18. Claus EB, Black PM, Bondy ML et al. Exogenous hormone use and meningioma risk: What do we tell our patients? Cancer 110(3), 471-476 (2007).
19. Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N. Engl. J. Med. 357(23), 2411-2412 (2007).
20. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: A population-based case-control study. BMC Cancer 6, 152 (2006).
21. Lamszus K. Meningioma pathology, genetics, and biology. J. Neuropathol. Exp. Neurol. 63(4), 275-286 (2004).
22. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A Phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. J. Neurooncol. 15(1), 75-77 (1993).
23. Grunberg SM, Weiss MH, Russell CA et al. Long-term administration of mifepristone (RU486): Clinical tolerance during extended treatment of meningioma. Cancer Invest. 24(8), 727-733 (2006).
24. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neurooncol. 99(3), 365-378 (2010).
25. Koper JW, Zwarthoff EC, Hagemeijer A et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur. J. Cancer 27(4), 416-419 (1991).
26. Chamberlain MC, Glantz MJ. Interferon- alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113(8), 2146-2151 (2008).
27. Arena S, Barbieri F, Thellung S et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J. Neurooncol. 66(1-2), 155-166 (2004).
28. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue. Neurology 69(10), 969-973 (2007).
29. Johnson DR, Kimmel DW, Burch PA et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-oncology 13(5), 530-535 (2011).
30. Norden AD, Hammond S, Drappatz J et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J. Clin. Oncol. 29 (2011).
31. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J. Neurooncol. 99(3), 315-324 (2010).
32. Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J. Clin. Neurosci. 8(Suppl. 1), 49-53 (2001).
33. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J. Neurosurg. 97(3), 668-675 (2002).
34. Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogenassociated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J. Neurosurg. 94(2), 293-300 (2001).
35. Wen PY, Yung WK, Lamborn KR et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-oncology 11(6), 853-860 (2009).
36. Reardon DA, Norden AD, Desjardins A et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J. Neurooncol. 106(2), 409-415 (2012).
37. Carroll RS, Black PM, Zhang J et al. Expression and activation of epidermal growth factor receptors in meningiomas. J. Neurosurg. 87(2), 315-323 (1997).
38. Jones NR, Rossi ML, Gregoriou M, Hughes JT. Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66(1), 152-155 (1990).
39. Norden AD, Raizer JJ, Abrey LE et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol. 96(2), 211-217 (2010).
40. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann. Oncol. 22(4), 990-991 (2011).
41. Collins IM, Beddy P, O'Byrne KJ. Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta Oncol. 49(6), 872-874 (2010).
42. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008).
43. Cook KM, Figg WD. Angiogenesis inhibitors: Current strategies and future prospects. CA. Cancer J. Clin. 60(4), 222-243 (2010).
44. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46(4), 938-947; discussion 947 (2000).
45. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: Role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 40(5), 1016-1026 (1997).
46. Goldman CK, Bharara S, Palmer CA et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40(6), 1269-1277 (1997).
47. Lou E, Sumrall AL, Turner S et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: A retrospective series. J. Neurooncol. 109, 63-70 (2012).
48. Lou E, Sumrall AL, Turner S et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: A retrospective series. J. Neurooncol. 109(1), 63-70 (2012).
49. Grimm SA, Chamberlain MC, Chandler J et al. A Phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. J. Clin. Oncol. 29 (2011).
50. Kaley TJ, Wen PY, Schiff D et al. Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neuro-oncol. 12(Suppl. 4), iv69-iv78 (2010).
51. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: Documentation of a series and analysis of cytogenetic findings. J. Neurosurg. 101(2), 210-218 (2004).
52. Rogers L, Mehta M. Role of radiation therapy in treating intracranial meningiomas. Neurosurg. Focus 23(4), E4 (2007).
53. McMullen KP, Stieber VW. Meningioma: Current treatment options and future directions. Curr. Treat. Options Oncol. 5(6), 499-509 (2004).
54. Pannullo SC, Fraser JF, Moliterno J, Cobb W, Stieg PE. Stereotactic radiosurgery: A meta-analysis of current therapeutic applications in neuro-oncologic disease. J. Neurooncol. 103(1), 1-17 (2011).
55. Reardon DA, Norden AD, Desjardins A et al. Phase II study of Gleevec plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J. Neurooncol. 106, 409-415 (2012).
56. Kaley TJ, Wen PY, Schiff D et al. Phase II trial of sunitinib in patients with recurrent or inoperable meningioma. Neurooncol. 11, 625 (2011) (abstract 264).
57. Raizer J, Grimm S, Chamberlain MC. PTK787 for recurrent and progressive meningioma. Neurooncol. 12(iv1-iv136), iv50 (2010).